Bio-Path Holdings prices $2.1M public offering of 3.5M shares and warrants at $0.60/unit

On August 3, 2023, Bio-Path Holdings, Inc., (the “Company”), entered into a placement agency agreement (the “Placement Agency Agreement”) with Roth Capital Partners, LLC (the “Placement Agent”) and a securities purchase agreement (the “Purchase Agreement”) with certain purchasers for the purchase and sale, in a registered public offering by the Company (the “Public Offering”), of an aggregate of 3,500,000 shares of its common stock, par value $0.001 per share (“Common Stock”), and accompanying common stock purchase warrants to purchase up to an aggregate of 3,500,000 shares of its Common Stock (the “Common Warrants”) at a combined public offering price of $0.60 per share of Common Stock and accompanying Common Warrant, resulting in gross proceeds of approximately $2.1 million.

On August 3, 2023, Bio-Path Holdings, Inc., (the “Company”), entered into a placement agency agreement (the “Placement Agency Agreement”) with Roth Capital Partners, LLC (the “Placement Agent”) and a securities purchase agreement (the “Purchase Agreement”) with certain purchasers for the purchase and sale, in a registered public offering by the Company (the “Public Offering”), of an aggregate of 3,500,000 shares of its common stock, par value $0.001 per share (“Common Stock”), and accompanying common stock purchase warrants to purchase up to an aggregate of 3,500,000 shares of its Common Stock (the “Common Warrants”) at a combined public offering price of $0.60 per share of Common Stock and accompanying Common Warrant, resulting in gross proceeds of approximately $2.1 million.

In connection with the Public Offering, the Company entered into warrant amendment letter agreements (the “Warrant Amendment Agreements”) to amend certain existing warrants to purchase up to an aggregate of 800,000 shares of the Company’s common stock that were previously issued on November 9, 2022 at an exercise price of $2.85 per share (the “Amended Warrants”), such that effective upon the closing of the Public Offering, the Amended Warrants have a reduced exercise price equal to $0.7593 per share.

On August 7, 2023, the Company also entered into a warrant agency agreement (the “Warrant Agency Agreement”) with the Company’s transfer agent, Equiniti Trust Company, LLC, who will act as warrant agent for the Company, setting forth the terms and conditions of the Common Warrants.